Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current MDGL market cap is 6.78B. The company's latest EPS is USD -17.1308 and P/E is -18.13.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 14.64M | 62.18M |
| Operating Income | -98.53M | -117.18M | -152.04M | -162.54M | -116.3M |
| Net Income | -98.74M | -112.19M | -147.54M | -151.97M | -106.96M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -94.97M | -206.67M | -242.48M | -293.57M | -380.5M |
| Net Income | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 237.96M | 640.55M | 1.08B | 1.1B | 1.07B |
| Total Liabilities | 215.72M | 235.21M | 231.52M | 242.67M | 296.11M |
| Total Equity | 22.25M | 405.33M | 850.76M | 857.12M | 777.16M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 442.06M | 287M | 273.33M | 362.57M | 640.55M |
| Total Liabilities | 25.49M | 47.03M | 77.23M | 165.18M | 235.21M |
| Total Equity | 416.57M | 239.97M | 196.11M | 197.39M | 405.33M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -244.3M | -324.23M | -149.16M | -284.1M | -351.09M |
| Investing | -140.4M | -502.52M | 98.05M | -24.05M | -226.44M |
| Financing | 115.2M | 595.12M | 573.71M | 707.83M | 715.29M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M |
| Investing | 30.71M | 159.78M | -5.06M | 206.69M | -502.52M |
| Financing | 235k | 5.09M | 171.24M | 313.45M | 595.12M |
| Market Cap | 6.78B |
| Price to Earnings Ratio | -18.13 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 67.79 |
| Price to Book Ratio | 16.71 |
| Dividend Yield | - |
| Shares Outstanding | 21.81M |
| Average Volume (1 week) | 458.07k |
| Average Volume (1 Month) | 345.93k |
| 52 Week Change | 31.87% |
| 52 Week High | 368.29 |
| 52 Week Low | 168.2462 |
| Spread (Intraday) | 109.87 (35.23%) |
| Company Name | Madrigal Pharmaceuticals Inc |
| Address |
2711 centerville road wilmington, delaware 19808 |
| Website | https://www.madrigalpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
